Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA reduced its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 6.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 144,199 shares of the biotechnology company’s stock after selling 9,845 shares during the quarter. Pictet Asset Management Holding SA owned about 0.24% of Ascendis Pharma A/S worth $19,852,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of ASND. Rice Hall James & Associates LLC lifted its holdings in Ascendis Pharma A/S by 2.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company’s stock valued at $22,562,000 after acquiring an additional 3,274 shares during the period. Nomura Asset Management Co. Ltd. increased its holdings in shares of Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock valued at $2,688,000 after purchasing an additional 5,371 shares in the last quarter. Maven Securities LTD acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at about $7,466,000. Exome Asset Management LLC boosted its holdings in Ascendis Pharma A/S by 119.2% during the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company’s stock worth $6,547,000 after buying an additional 23,849 shares in the last quarter. Finally, abrdn plc grew its position in Ascendis Pharma A/S by 18.3% during the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company’s stock worth $25,769,000 after buying an additional 28,967 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ASND. JPMorgan Chase & Co. boosted their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 18th. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a report on Tuesday, February 18th. UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target for the company. The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, Evercore ISI lifted their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $204.64.

Ascendis Pharma A/S Stock Up 0.8 %

ASND stock opened at $155.86 on Tuesday. The stock has a market capitalization of $9.46 billion, a price-to-earnings ratio of -21.95 and a beta of 0.62. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $169.37. The stock’s fifty day simple moving average is $144.72 and its 200-day simple moving average is $137.63.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. As a group, analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.